Effect of airway clearance device on function and quality of life in stable ICU patients.
- Conditions
- Health Condition 1: J99- Respiratory disorders in diseasesclassified elsewhere
- Registration Number
- CTRI/2022/12/048008
- Lead Sponsor
- MGM College of Physiotherapy
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
(1)Patients who are spontaneously breathing or on non-invasive ventilatory support in intensive care unit
(2) Patients extubated for more than 8 hours who were previously intubated
(3) Patients showing radiographic changes of sputum retention, consolidation and pulmonary infiltrates
(4) Patients who are above 18 years
(5) Patient who consent to participate
(1)Patients who are hemodynamically unstable
(2)Patients with untreated pneumothorax, emphysematous bullae, rib fractures etc
(3)History of any recent major cardiac and neurosurgery
(4)Patients who are tracheostomized during the ICU stay
(5)Any neuro-musculoskeletal disorder that prevents them from performing the tests
(6)Patients with cognitive impairment that prevents them from understanding the instructions
(7)Patients who are agitated or sedated as assessed using Richmond Agitation Sedation Scale (RASS more than -1 or +1)
(8)Participant who are not willing to participate
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary outcome/s(1)Lung function : Pulmonary function (FEV1, FVC) , Respiratory muscle strength (Maximal Inspiratory Pressure, Maximal Expiratory Pressure), <br/ ><br>Chest expansion (at three levels namely axilla, nipple and xiphisternum) <br/ ><br>Sputum quantity would be assessed by measuring the sputum volume. <br/ ><br> <br/ ><br>(2)Physical performance: Short Physical Performance Battery test score <br/ ><br>(3)Functional capacity : Repetitions in 30 seconds Sit to Stand test <br/ ><br> (4)Quality of Life: EQ 5D 3L questionnaire score <br/ ><br>Timepoint: At Baseline <br/ ><br>At 4 weeks
- Secondary Outcome Measures
Name Time Method (1)Sarcopenia using SARC-calf scale. <br/ ><br>(2)Frailty using Fried Frailty Index. <br/ ><br> (3)ICU acquired weakness using Medical Research Council (MRC) sum score. <br/ ><br>Timepoint: At Baseline <br/ ><br>At 4 weeks